VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
Key facts
- Who runs it
- Tiohundra AB
- Where
- Sweden4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 784 people, planned
- Started
- 12 Oct 2026
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vasopressin; Methylprednisolone; Hydrocortisone
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Witnessed inhospital cardiac arrest, who meet the criteria for adrenaline administration according to current ERC guidelines
- Men > 18 years and women > 50 years
Who cannot take part
- Peroperative cardiac arrest
- Out of hospital cardiac arrest, including rearrest at the emergency department or the intensive care unit
- Patients with a do not resuscitate (DNR) decision
This trial is currently available in Sweden.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an investigator initiated randomized, placebo controlled, open label, superiority, multi-centre clinical trial. The estimated study project period runs over 3-4 years, after now completed pilot phase. Based on preliminary assumptions, to confirm or reject an increase in survival from 16% to 24%, about 784 patients will be randomized in the study. In hospital cardiac arrest patients meeting criteria(s) for adrenaline administration according to current ERC guidelines, men > 18 years and women > 50, are eligible for randomization in the study.
Read full original descriptionShow less
Patients with do not resuscitate (DNR) decision will be excluded. Patients will be randomized to, in addition to adrenaline, either treatment with vasopressin and steroids (intervention) or standard care (control) Primary outcome is survival at 30 days.
The 2 groups in the trial
- InterventionExisting treatment, for comparison
Adrenaline, vasopressin and steroids arm (intervention) 1. At randomization 1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR. 1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR 2. In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 5 days.
Treatment: Vasopressin; Methylprednisolone; Hydrocortisone
- ControlNo study treatment, for comparison
Standard care in cardiac arrest
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Publications
- Record updated
- 12 November 2026